Integrative O
Transcriptomics O
Reveals O
Sexually O
Dimorphic O
Control O
of O
the O
Cholinergic/Neurokine O
Interface O
in O
Schizophrenia O
and O
Bipolar O
Disorder O
Summary O
RNA O
sequencing O
analyses O
are O
often O
limited O
to O
identifying O
lowest O
p O
value O
transcripts O
, O
which O
does O
not O
address O
polygenic O
phenomena O
. O

To O
overcome O
this O
limitation O
, O
we O
developed O
an O
integrative O
approach O
that O
combines O
large-scale O
transcriptomic O
meta-analysis O
of O
patient O
brain O
tissues O
with O
single-cell O
sequencing O
data O
of O
CNS O
neurons O
, O
short O
RNA O
sequencing O
of O
human O
male- O
and O
female-originating O
cell O
lines O
, O
and O
connectomics O
of O
transcription O
factor O
and O
microRNA O
interactions O
with O
perturbed O
transcripts O
. O

We O
used O
this O
pipeline O
to O
analyze O
cortical O
transcripts O
of O
schizophrenia O
and O
bipolar O
disorder O
patients O
. O

Although O
these O
pathologies O
show O
massive O
transcriptional O
parallels O
, O
their O
clinically O
well-known O
sexual O
dimorphisms O
remain O
unexplained O
. O

Our O
method O
reveals O
the O
differences O
between O
afflicted O
men O
and O
women O
and O
identifies O
disease-affected O
pathways O
of O
cholinergic O
transmission O
and O
gp130-family O
neurokine O
controllers O
of O
immune O
function O
interlinked O
by O
microRNAs O
. O

This O
approach O
may O
open O
additional O
perspectives O
for O
seeking O
biomarkers O
and O
therapeutic O
targets O
in O
other O
transmitter O
systems O
and O
diseases O
. O

Graphical O
Abstract O
Highlights O
Single-cell O
transcriptomes O
reveal O
a O
unique O
profile O
of O
cortical O
cholinergic O
neurons O
Female- O
and O
male-derived O
cells O
show O
distinct O
neurokine-induced O
miRNA O
responses O
Differentially O
enriched O
microRNA O
families O
constitute O
a O
self-organizing O
network O
Integrative O
analysis O
identifies O
mir-10/mir-199 O
regulators O
of O
cholinergic O
function O
Lobentanzer O
et O
al O
. O

show O
how O
bioinformatically O
supported O
high-throughput O
techniques O
such O
as O
short O
RNA O
sequencing O
can O
bridge O
the O
gap O
between O
traditional O
molecular O
interaction O
studies O
and O
purely O
bioinformatic O
prediction O
paradigms O
in O
an O
example O
focused O
on O
disentangling O
the O
sexual O
dimorphism O
in O
microRNA O
regulation O
of O
the O
cholinergic/neurokine O
interface O
in O
mental O
disorders O
. O

STAR★Methods O
Key O
Resources O
Table O
Lead O
Contact O
and O
Materials O
Availability O
Further O
information O
and O
requests O
for O
resources O
and O
reagents O
should O
be O
directed O
to O
and O
will O
be O
fulfilled O
by O
the O
Lead O
Contact O
, O
Hermona O
Soreq O
( O
hermona.soreq O
@ O
mail.huji.ac.il O
) O
. O

This O
study O
did O
not O
generate O
new O
unique O
reagents O
. O

Experimental O
Model O
and O
Subject O
Details O
Cell O
Lines O
We O
employed O
LA-N-2 O
( O
female O
) O
( O
DSMZ O
Cat O
# O
ACC-671 O
, O
RRID O
: O
CVCL_1829 O
) O
and O
LA-N-5 O
( O
male O
) O
( O
DSMZ O
Cat O
# O
ACC-673 O
, O
RRID O
: O
CVCL_0389 O
) O
cells O
as O
our O
main O
experimental O
model O
system O
. O

The O
cells O
were O
purchased O
at O
DSMZ O
( O
Braunschweig O
, O
Germany O
) O
. O

These O
cells O
respond O
to O
differentiation O
by O
several O
neurokines O
( O
CNTF O
, O
LIF O
, O
IL-6 O
) O
by O
cholinergic O
differentiation O
corresponding O
with O
elevation O
of O
choline O
acetyltransferase O
( O
ChAT O
) O
, O
the O
central O
cholinergic O
marker O
( O
mRNA O
, O
protein O
, O
and O
activity O
) O
as O
well O
as O
its O
intronic O
vesicular O
ACh-transporter O
gene O
, O
vAChT O
( O
aka O
SLC18A3 O
) O
. O

Cells O
were O
maintained O
at O
37°C O
in O
8 O
% O
CO2 O
atmosphere O
in O
medium O
consisting O
of O
1:1 O
DMEM O
and O
RPMI O
1640 O
, O
with O
20 O
% O
FCS O
, O
with O
weekly O
splits O
. O

Experiments O
were O
performed O
between O
splits O
2-6 O
after O
thawing O
. O

HEK293T O
and O
U937 O
cells O
were O
purchased O
at O
ATCC O
and O
maintained O
according O
to O
ATCC O
guidelines O
. O

Experiments O
were O
performed O
between O
splits O
2-10 O
. O

Human O
Patient O
Data O
We O
used O
previously O
published O
datasets O
for O
several O
analyses O
. O

These O
comprise O
several O
cortical O
datasets O
in O
raw O
format O
( O
Affymetrix O
) O
from O
NCBI O
GEO O
: O
GSE35978 O
( O
SCZ O
& O
BD O
) O
, O
GSE53987 O
( O
SCZ O
& O
BD O
) O
, O
GSE12649 O
( O
SCZ O
& O
BD O
) O
, O
GSE17612 O
( O
SCZ O
) O
, O
GSE21138 O
( O
SCZ O
) O
, O
GSE5392 O
( O
BD O
) O
; O
next-generation O
sequencing O
from O
NCBI O
GEO O
: O
GSE80655 O
, O
GSE106589 O
, O
GSE68559 O
, O
GSE96659 O
, O
GSE45642 O
; O
data O
of O
DLPFC O
sequencing O
of O
600 O
SCZ O
patients O
and O
controls O
was O
obtained O
from O
the O
Common O
Mind O
Consortium O
( O
http O
: O
//www.synapse.org/CMC O
) O
. O

Method O
Details O
Methodological O
Outline O
Focusing O
on O
a O
well-defined O
set O
of O
genes O
aims O
to O
avoid O
some O
of O
the O
data O
loss O
that O
occurs O
when O
patient O
tissues O
comprising O
multiple O
cell O
types O
are O
homogenized O
for O
analysis O
. O

This O
is O
particularly O
relevant O
for O
cortical O
cholinergic O
interneurons O
, O
where O
the O
cell O
type O
of O
interest O
is O
numerically O
inferior O
, O
and O
transcriptomic O
data O
can O
be O
“ O
diluted O
” O
by O
the O
other O
, O
more O
prominent O
cell O
types O
, O
such O
as O
glia O
or O
astrocytes O
. O

The O
consequent O
increase O
in O
detection O
threshold O
can O
be O
re-lowered O
by O
reducing O
the O
number O
of O
genes O
tested O
. O

Analysis O
of O
single O
cell O
datasets O
can O
ascertain O
that O
the O
genes O
analyzed O
are O
representative O
and O
fairly O
unique O
to O
the O
cell O
type O
in O
question O
, O
as O
was O
the O
case O
for O
cholinergic O
markers O
in O
our O
study O
, O
and O
utmost O
care O
should O
be O
taken O
for O
any O
gene O
set O
of O
interest O
and O
any O
kind O
of O
tissue O
subjected O
to O
this O
kind O
of O
analysis O
. O

Our O
approach O
is O
based O
on O
the O
availability O
of O
suitable O
amounts O
of O
patient O
data O
in O
web-available O
form O
, O
combined O
with O
a O
standardized O
pipeline O
of O
statistical O
pre-processing O
to O
equilibrate O
individual O
statistical O
influences O
. O

Regardless O
of O
how O
patient O
data O
and O
the O
subset O
of O
genes O
of O
interest O
are O
selected O
, O
the O
reduction O
in O
number O
of O
analyzed O
genes O
has O
to O
be O
performed O
after O
application O
of O
the O
linear O
model O
to O
the O
batch- O
and O
covariate-corrected O
data O
to O
avoid O
interference O
with O
correct O
linear O
regression O
. O

Once O
the O
expression O
data O
( O
be O
it O
array- O
or O
sequencing-derived O
) O
has O
been O
corrected O
for O
batch O
effects O
and O
covariates O
, O
and O
outliers O
have O
been O
removed O
, O
it O
can O
be O
analyzed O
with O
a O
suitable O
differential O
gene O
expression O
algorithm O
. O

The O
resulting O
, O
individual O
datasets O
should O
ideally O
converge O
on O
similar O
logFC O
values O
, O
but O
may O
also O
show O
controversy O
between O
individual O
experiments O
, O
which O
can O
result O
from O
a O
multitude O
of O
factors O
from O
biological O
variety O
to O
sampling O
procedures O
or O
exact O
tissue O
composition O
, O
all O
of O
which O
have O
to O
be O
interpreted O
at O
the O
discretion O
of O
the O
scientist O
. O

Neuronal O
Differentiation/Short O
RNA O
Sequencing O
Model O
LA-N-2 O
and O
LA-N-5 O
cells O
respond O
to O
ciliary O
neurotrophic O
factor O
( O
CNTF O
) O
by O
cholinergic O
differentiation O
corresponding O
with O
elevation O
of O
choline O
acetyltransferase O
( O
ChAT O
) O
, O
the O
central O
cholinergic O
marker O
( O
mRNA O
, O
protein O
, O
and O
activity O
) O
as O
well O
as O
its O
intronic O
vesicular O
ACh-transporter O
gene O
, O
vAChT O
( O
aka O
SLC18A3 O
) O
. O

We O
measured O
the O
changes O
in O
short O
RNA O
levels O
following O
this O
intervention O
at O
several O
time O
points O
. O

Differentiation O
To O
determine O
effective O
concentrations O
of O
the O
differentiation O
agent O
, O
we O
performed O
a O
dose-response O
experiment O
with O
both O
cell O
lines O
. O

Cells O
were O
seeded O
at O
approximately O
200 O
000 O
cells O
per O
well O
in O
12-well O
plates O
, O
and O
after O
24h O
incubated O
with O
1 O
, O
10 O
, O
or O
100 O
ng/ml O
CNTF O
( O
Sigma-Aldrich O
) O
. O

Dose-response O
was O
measured O
by O
qPCR O
of O
CHAT O
mRNA O
, O
at O
time O
points O
30 O
minutes O
, O
60 O
minutes O
, O
2 O
days O
, O
and O
4 O
days O
. O

For O
each O
sample O
, O
a O
corresponding O
control O
culture O
was O
generated O
. O

RNA O
Extraction O
for O
qPCR O
and O
Sequencing O
RNA O
was O
extracted O
in O
biological O
quadruplicates O
using O
TRIzol O
according O
to O
the O
manufacturer′s O
instructions O
, O
as O
described O
in O
. O

RNA O
was O
precipitated O
using O
ethanol O
, O
washed O
, O
and O
air-dried O
before O
resuspension O
in O
RNase-free O
water O
. O

Concentration O
was O
measured O
by O
Nanodrop O
2000 O
( O
ThermoFisher O
Scientific O
) O
, O
RNA O
quality O
was O
measured O
via O
Bioanalyzer O
2100 O
( O
Agilent O
) O
. O

RNA O
quality O
for O
all O
samples O
was O
near O
optimal O
( O
RIN O
> O
9 O
) O
. O

Quantitative O
Real-time O
PCR O
RNA O
was O
analyzed O
on O
a O
BioRad O
CFX96 O
real-time O
PCR O
cycler O
using O
PowerUp O
SYBR O
Green O
Master O
Mix O
( O
Applied O
Biosystems O
) O
in O
technical O
duplicates O
. O

Primers O
were O
designed O
using O
primer3 O
and O
are O
as O
follows O
( O
5′ O
to O
3′ O
) O
: O
ChAT O
[ O
FW O
: O
CAC O
TTG O
GTG O
TCT O
GAG O
CA O
, O
RV O
: O
AGT O
TTC O
TGC O
TGC O
AGG O
GTC O
TC O
] O
, O
ACTB O
( O
housekeeping O
) O
[ O
FW O
: O
GCT O
GTA O
TTC O
CCC O
TCC O
ATC O
GT O
, O
RV O
: O
CTT O
CTC O
CAT O
GTC O
GTC O
CCA O
GT O
] O
; O
additional O
primers O
were O
ordered O
from O
BioRad O
, O
Germany O
: O
vAChT O
[ O
PrimePCR O
“ O
qHsaCED0047922 O
” O
] O
, O
RPLP0 O
( O
housekeeping O
) O
[ O
PrimePCR O
“ O
qHsaCED0038653 O
” O
] O
. O

Data O
were O
analyzed O
with O
BioRad O
CFX O
manager O
and O
expression O
values O
( O
normalized O
to O
housekeeping O
genes O
) O
exported O
for O
statistical O
testing O
in O
R. O
Short O
RNA O
Sequencing O
Short O
RNA O
sequencing O
was O
performed O
using O
Illumina O
NextSeq O
550 O
according O
to O
the O
manufacturer O
’ O
s O
instructions O
, O
after O
cDNA O
library O
preparation O
using O
the O
NEBNext O
Multiplex O
Small O
RNA O
Library O
Prep O
Set O
for O
Illumina O
( O
New O
England O
BioLabs O
) O
as O
described O
. O

Sequenced O
reads O
were O
aligned O
to O
miRBase O
v21 O
sequences O
via O
miRExpress O
( O
version O
2.1.4 O
) O
. O

Differential O
expression O
was O
determined O
via O
R/DESeq2 O
. O

The O
Count-Change O
Metric O
We O
calculated O
the O
count-change O
for O
individual O
miRs O
by O
combining O
base O
mean O
expression O
with O
the O
de-logarithmized O
fold-change O
( O
from O
DESeq2 O
output O
) O
.CC O
: O
countChange O
, O
BM O
: O
baseMean O
, O
LFC O
: O
log2-fold O
change O
It O
is O
important O
to O
note O
that O
the O
count-change O
metric O
, O
by O
deriving O
from O
the O
base O
mean O
expression O
across O
samples O
, O
is O
dependent O
on O
sequencing O
depth O
, O
and O
thus O
is O
not O
instantly O
generalizable O
, O
for O
instance O
when O
comparing O
different O
experiments O
. O

However O
, O
it O
could O
be O
normalized O
to O
a O
degree O
by O
considering O
the O
total O
amount O
of O
raw O
reads O
generated O
from O
each O
sample O
. O

Whole-Transcriptome O
Meta-analysis O
Data O
Preparation O
We O
processed O
web-available O
patient O
transcriptome O
datasets O
by O
state-of-the-art O
procedures O
, O
analogous O
to O
, O
to O
generate O
transcriptional O
disease O
profiles O
. O

The O
following O
R O
packages O
( O
Bioconductor O
) O
were O
used O
according O
to O
the O
developer O
’ O
s O
instructions O
: O
Raw O
data O
read O
, O
RMA O
normalization O
, O
RNA O
degradation O
: O
affy O
. O

Batch O
correction O
( O
as O
per O
chip O
scan O
date O
) O
involved O
: O
sva O
( O
Combat O
) O
. O

Outliers O
were O
removed O
as O
described O
in O
. O

The O
array O
probes O
were O
annotated O
via O
ENSEMBL O
gene O
ID O
, O
database O
version O
v75 O
, O
to O
ensure O
congruency O
with O
prior O
analyses O
, O
using O
biomaRt O
, O
and O
were O
collapsed O
via O
the O
collapseRows O
function O
of O
WGCNA O
. O

Prior O
to O
application O
of O
the O
generalized O
linear O
mixed O
model O
( O
nlme O
) O
, O
datasets O
were O
rebalanced O
and O
regressed O
to O
correct O
for O
technical O
and O
biological O
covariate O
influences O
. O

Regression O
Analysis O
Meta-analysis O
on O
all O
genes O
present O
in O
all O
datasets O
( O
12,391 O
genes O
in O
total O
) O
employed O
a O
generalized O
linear O
mixed O
model O
to O
account O
for O
variation O
per O
dataset O
and O
individual O
, O
yielding O
log2-fold O
change O
( O
logFC O
) O
values O
for O
each O
gene O
between O
control O
and O
disease O
, O
which O
were O
correlated O
between O
SCZ O
and O
BD O
using O
Spearman O
’ O
s O
method O
. O

To O
determine O
significance O
, O
the O
meta-analysis O
process O
was O
repeated O
10,000 O
times O
with O
randomized O
case/control O
status O
, O
forming O
a O
permutation O
null O
distribution O
of O
the O
individual O
correlation O
coefficients O
( O
Figure O
S3 O
) O
. O

Of O
note O
, O
several O
cholinergic O
and O
neurokine O
genes O
were O
missing O
from O
the O
whole-genome O
meta-analysis O
because O
of O
annotation O
deficits O
( O
CHRNA7 O
, O
CHRM1 O
, O
LHX8 O
, O
CHKB O
, O
PRIMA1 O
, O
CNTF O
) O
, O
and O
, O
at O
this O
stage O
, O
could O
not O
be O
easily O
re-introduced O
. O

Gene O
Ontology O
( O
GO O
) O
Enrichment O
Analyses O
To O
focus O
on O
the O
differences O
, O
as O
opposed O
to O
the O
similarities O
, O
between O
BD O
and O
SCZ O
patient O
brain O
transcriptomes O
, O
we O
performed O
GO O
enrichment O
analysis O
on O
the O
genes O
showing O
the O
highest O
rank O
differences O
between O
datasets O
( O
Figure O
S4 O
) O
, O
using O
the O
R O
package O
topGO O
. O

Briefly O
, O
we O
evaluated O
( O
smaller O
) O
groups O
of O
genes O
for O
enrichment O
against O
a O
( O
bigger O
) O
background O
of O
genes O
for O
presence O
in O
individual O
GO O
terms O
exceeding O
statistical O
estimates O
. O

The O
background O
comprised O
of O
the O
first O
2000 O
genes O
according O
to O
the O
applied O
rank O
system O
, O
computed O
as O
a O
function O
of O
Spearman O
’ O
s O
rank O
differences O
of O
regression O
beta O
values O
( O
logFC O
) O
between O
the O
two O
compared O
groups O
, O
either O
as O
absolute O
values O
or O
“ O
as O
is O
” O
( O
elevation O
in O
one O
group O
as O
opposed O
to O
the O
other O
) O
. O

The O
target O
genes O
of O
the O
analysis O
were O
defined O
as O
the O
100 O
top O
ranked O
genes O
( O
top O
5 O
% O
of O
background O
) O
, O
unless O
otherwise O
stated O
. O

Statistically O
significant O
GO O
results O
were O
compiled O
and O
curated O
for O
CNS-relevant O
terms O
. O

Sex O
Influence O
on O
Transcriptomic O
Differences O
Studying O
web-available O
datasets O
of O
non-degenerative O
mental O
disease O
patients O
revealed O
that O
SCZ O
and O
BD O
datasets O
possessed O
sufficient O
numbers O
to O
allow O
sex-discriminative O
meta-analysis O
of O
statistical O
significance O
. O

Hence O
, O
we O
repeated O
the O
above O
steps O
for O
the O
individual O
subsets O
of O
male O
and O
female O
patients O
, O
with O
the O
sole O
change O
of O
eliminating O
the O
covariate O
regression O
for O
sex O
, O
as O
this O
would O
preclude O
further O
analysis O
of O
this O
variable O
, O
in O
4 O
distinct O
GO O
enrichment O
group O
comparisons O
between O
SCZ-biased O
, O
BD-biased O
, O
male-biased O
, O
and O
female-biased O
genes O
. O

miR-gene-TF-targeting O
: O
miRNet O
To O
address O
miR-mRNA O
targeting O
relations O
, O
we O
developed O
an O
integrated O
miR-targeting O
graph O
database O
( O
‘ O
miRNet O
’ O
) O
out O
of O
publicly O
available O
validated O
and O
predicted O
data O
, O
implementing O
a O
scoring O
system O
derived O
from O
10 O
leading O
prediction O
algorithms O
based O
on O
their O
statistical O
performance O
at O
the O
whole-genome O
level O
. O

To O
facilitate O
the O
selection O
process O
, O
targeting O
data O
were O
cumulated O
by O
summing O
the O
amount O
of O
positive O
“ O
hits O
” O
of O
prediction O
algorithms O
( O
1 O
point O
) O
and O
positive O
experimental O
validations O
( O
only O
“ O
strong O
” O
evidence O
, O
miRTarBase O
, O
10,5 O
points O
) O
of O
the O
targeting O
relationship O
, O
yielding O
a O
targeting O
score O
between O
0 O
and O
20,5 O
. O

We O
found O
a O
minimal O
score O
of O
6 O
to O
suffice O
for O
a O
good O
balance O
between O
type O
I O
and O
II O
errors O
. O

In O
case O
of O
whole-genome O
interactions O
, O
this O
threshold O
was O
raised O
to O
7 O
to O
enable O
computational O
accessibility O
in O
all O
steps O
( O
in O
this O
case O
, O
graphical O
analysis O
was O
the O
bottleneck O
) O
. O

The O
database O
was O
supplemented O
by O
comprehensive O
transcription O
factor O
targeting O
data O
via O
bioinformatically O
processed O
“ O
cap O
analysis O
of O
gene O
expression O
” O
( O
CAGE O
) O
, O
focusing O
on O
brain O
tissues O
, O
including O
the O
tissue-specific O
transcriptional O
activities O
( O
Figure O
S5 O
) O
. O

The O
code O
used O
to O
create O
and O
test O
this O
database O
is O
available O
in O
the O
accompanying O
repository O
. O

A O
public O
release O
is O
planned O
, O
but O
not O
completed O
at O
the O
moment O
; O
requests O
can O
be O
directed O
at O
the O
corresponding O
author O
. O

Analyses O
performed O
using O
this O
database O
were O
implemented O
in O
R O
using O
the O
‘ O
RNeo4j O
’ O
package O
. O

Limitations O
Through O
recent O
methodical O
and O
bioinformatical O
advances O
, O
targeting O
data O
of O
transcription O
factors O
and O
miRs O
has O
become O
comprehensive O
. O

However O
, O
these O
“ O
complete O
” O
datasets O
are O
subject O
to O
limitations O
derived O
from O
the O
methods O
used O
to O
accumulate O
raw O
data O
. O

For O
TF-targeting O
, O
CAGE O
5′ O
peaks O
were O
analyzed O
toward O
their O
correlation O
with O
gene O
expression O
in O
all O
available O
tissues O
. O

A O
cholinergic O
example O
of O
limitations O
derived O
from O
this O
data O
involves O
the O
CHAT O
gene O
, O
which O
does O
not O
provide O
a O
measurable O
CAGE O
peak O
, O
leading O
to O
non-representation O
in O
the O
targeting O
dataset O
. O

In O
those O
cases O
, O
targeting O
data O
acquired O
through O
conventional O
methods O
have O
to O
be O
substituted O
, O
but O
this O
can O
not O
be O
easily O
done O
for O
all O
affected O
genes O
, O
and O
is O
also O
not O
comprehensive O
. O

In O
the O
case O
of O
miR-targeting O
, O
validated O
interactions O
are O
based O
on O
experimental O
work O
mainly O
performed O
on O
rodents O
, O
leading O
to O
a O
research O
bias O
toward O
evolutionarily O
conserved O
miRs O
. O

Primate-specific O
miRs O
therefore O
are O
under-represented O
, O
at O
least O
in O
validated O
data O
. O

Permutation O
Targeting O
Analyses O
In O
the O
current O
state O
of O
comprehensive O
data O
on O
miR-gene O
( O
and O
TF-gene O
) O
targeting O
, O
no O
statements O
can O
be O
made O
with O
absolute O
certainty O
. O

Thus O
, O
an O
approach O
which O
considers O
relative O
measures O
is O
preferable O
. O

For O
this O
reason O
, O
whenever O
whole-genome/whole-miRnome O
targeting O
was O
concerned O
, O
we O
employed O
random O
permutation O
of O
the O
prediction O
dataset O
or O
each O
single O
predicted O
miR O
against O
a O
randomized O
background O
of O
the O
same O
size O
as O
the O
original O
set O
( O
also O
considering O
family- O
and O
precursor-relationships O
) O
. O

The O
resulting O
null O
distribution O
yields O
a O
basis O
for O
determination O
of O
a O
false O
discovery O
rate O
. O

Neurokine-Induced O
miRs O
and O
the O
Cholinergic/Neurokine O
Pathway O
Gene O
targets O
of O
the O
490 O
differentially O
regulated O
miRs O
following O
CNTF O
exposure O
were O
determined O
by O
miRNet O
query O
( O
targeting O
score O
minimum O
of O
6 O
) O
. O

The O
full O
network O
, O
originally O
comprising O
∼160,000 O
unique O
relationships O
, O
was O
re-filtered O
by O
raising O
the O
threshold O
to O
score O
minimum O
of O
7 O
to O
be O
computationally O
accessible O
. O

The O
resulting O
network O
and O
individual O
miR-family-subnetworks O
were O
plotted O
using O
a O
force-directed O
layout O
( O
Force O
Atlas O
2 O
) O
in O
gephi O
. O

Single-Cell O
Sequencing O
Dataset O
Analysis O
and O
Permutation O
We O
analyzed O
4 O
web-available O
datasets O
of O
brain O
single O
cell O
gene O
expression O
for O
neurokine O
signaling O
transcripts O
in O
cholinergic O
neurons O
, O
identified O
by O
their O
expression O
of O
the O
ACh-synthesizing O
enzyme O
choline O
acetyltransferase O
( O
ChAT O
) O
, O
and O
its O
embedded O
gene O
encoding O
the O
vesicular O
acetylcholine O
transporter O
SLC18A3 O
, O
also O
known O
as O
vAChT O
. O

Raw O
gene O
expression O
data O
were O
normalized O
and O
then O
clustered O
and O
plotted O
via O
R/pheatmap O
. O

The O
genes O
expressed O
in O
more O
than O
one O
sample O
per O
dataset O
were O
enriched O
for O
targeting O
of O
TFs O
and O
miRs O
by O
random O
permutation O
analysis O
( O
via O
miRNet O
) O
, O
with O
10 O
000 O
permutations O
for O
conserved O
and O
primate O
miR-target O
relationships O
, O
and O
human O
CNS O
TF O
interactions O
. O

Subset O
Analyses O
Cholinergic O
Genes O
, O
Transcription O
Factor O
, O
and O
Neurokine O
Analyses O
To O
follow O
our O
cholinergic O
interest O
, O
we O
used O
a O
recent O
review O
to O
define O
a O
core O
set O
of O
genes O
, O
adding O
to O
it O
the O
neurokine O
and O
circadian O
pathway O
genes O
indicated O
in O
the O
previous O
analyses O
( O
to O
a O
total O
of O
76 O
genes O
) O
. O

Via O
miRNet O
permutation O
( O
Data O
S2 O
) O
, O
we O
identified O
18 O
brain-expressed O
“ O
cholinergic O
” O
TFs O
( O
p O
< O
0.05 O
) O
and O
their O
CNS O
transcriptional O
activity O
toward O
each O
targeted O
cholinergic O
gene O
. O

These O
94 O
genes O
( O
Data O
S7 O
) O
were O
then O
subjected O
to O
differential O
expression O
analysis O
in O
the O
deposited O
patient O
datasets O
. O

Execution O
of O
Subset O
Analyses O
To O
separately O
analyze O
male O
and O
female O
data O
in O
the O
original O
datasets O
, O
we O
repeated O
the O
sex-independent O
analyses O
of O
the O
identified O
94 O
cholinergic O
genes O
and O
TFs O
using O
the O
limma O
pipeline O
. O

Pre-processing O
was O
identical O
to O
the O
whole-transcriptome O
approach O
, O
and O
dataset O
reduction O
involved O
restricting O
the O
output O
table O
( O
topTable O
( O
) O
function O
) O
to O
the O
studied O
genes O
. O

This O
further O
allowed O
controlling O
of O
missing O
genes O
of O
interest O
by O
manually O
solving O
problems O
of O
annotation O
, O
which O
in O
a O
whole-genome O
analysis O
would O
have O
led O
to O
loss O
of O
information O
on O
, O
e.g. O
, O
the O
nicotinic O
α7 O
and O
stress-responding O
M1 O
cholinergic O
receptors O
. O

miR-125b-5p O
Validation O
To O
test O
binding O
of O
hsa-miR-125b-5p O
to O
the O
acetylcholinesterase O
( O
AChE O
) O
3′-UTR O
, O
we O
performed O
vector-based O
assays O
via O
suppression O
of O
a O
cytotoxic O
sensor O
as O
well O
as O
of O
Renilla O
luciferase O
, O
both O
fused O
to O
the O
AChE-3′-UTR O
. O

Briefly O
, O
the O
3′ O
untranslated O
region O
( O
3′-UTR O
) O
of O
human O
AChE O
mRNA O
was O
cloned O
into O
the O
microRNA O
Target O
Selection O
System O
plasmid O
( O
System O
Biosciences O
, O
CA O
, O
USA O
) O
multiple O
cloning O
site O
, O
using O
EcoRI O
and O
NotI O
restriction O
enzymes O
( O
New O
England O
Biolabs O
) O
. O

All O
plasmids O
were O
verified O
by O
DNA O
sequencing O
. O

For O
luciferase O
assays O
, O
HEK293T O
cells O
were O
transfected O
with O
miRNA O
Target O
Selection-AChE-3′UTR O
, O
and O
selected O
in O
the O
presence O
of O
Puromycin O
for O
3 O
weeks O
. O

Stably O
transfected O
HEK293T O
( O
293T-AChE O
3′UTR O
) O
cells O
were O
grown O
on O
12-well O
plates O
and O
infected O
with O
lentiviruses O
expressing O
miR-125b-5p O
, O
miR-132-3p O
or O
a O
negative O
control O
sequence O
. O

After O
48 O
hours O
incubation O
, O
cells O
were O
analyzed O
using O
the O
Dual O
Luciferase O
Assay O
kit O
( O
Promega O
, O
WI O
USA O
) O
and O
Luciferase O
activity O
was O
measured O
using O
an O
Envision O
luminescent O
plate O
reader O
( O
Perkin-Elmer O
, O
Waltham O
, O
MA O
) O
, O
essentially O
as O
previously O
described O
. O

For O
each O
reporter O
construct O
, O
renilla O
luciferase O
activity O
was O
normalized O
according O
to O
that O
of O
the O
firefly O
. O

Normalized O
activity O
after O
infection O
of O
miR-132-3p O
or O
miR-125b-5p O
was O
expressed O
as O
relative O
to O
that O
obtained O
after O
infection O
with O
the O
same O
plasmid O
with O
miR O
negative O
control O
. O

For O
life/death O
assay O
, O
a O
similar O
protocol O
was O
used O
. O

Stably O
transfected O
HEK293T O
( O
293T-AChE O
3′UTR O
) O
cells O
were O
infected O
with O
lentiviruses O
expressing O
miR-125b-5p O
, O
miR-132-3p O
or O
a O
negative O
control O
sequence O
. O

72 O
hours O
post-infection O
a O
cytotoxic O
reporter O
fused O
to O
AChE O
3′-UTR O
was O
added O
to O
the O
media O
and O
cells O
were O
kept O
for O
an O
additional O
5 O
days O
to O
assess O
their O
viability O
. O

Statistical O
significance O
was O
determined O
using O
ANOVA O
with O
correction O
for O
multiple O
testing O
. O

To O
show O
effects O
of O
changes O
in O
this O
miR O
’ O
s O
levels O
on O
real-life O
protein O
activities O
, O
we O
performed O
an O
AChE O
hydrolytic O
activity O
assay O
following O
infection O
of O
human O
monocyte-like O
U937 O
cells O
with O
hsa-miR-125b-5p O
, O
miR-132-3p O
or O
a O
negative O
control O
lentiviral O
vector O
. O

AChE O
hydrolytic O
activity O
levels O
were O
assessed O
by O
kinetic O
measurements O
of O
the O
hydrolysis O
rates O
of O
1 O
mM O
acetylthiocholine O
( O
ATCh O
, O
Sigma O
) O
at O
room O
temperature O
, O
following O
20 O
min O
incubation O
with O
and O
without O
5x10−5 O
M O
tetraisopropyl O
pyrophosphoramide O
( O
iso-OMPA O
, O
Sigma O
) O
, O
a O
specific O
inhibitor O
of O
butyrylcholinesterase O
, O
to O
selectively O
assay O
for O
AChE-specific O
or O
total O
cholinesterase O
activity O
. O

Each O
sample O
was O
assayed O
in O
at O
least O
3 O
biological O
replicates O
. O

In O
all O
cases O
, O
hsa-miR-132-3p O
served O
as O
a O
positive O
control O
. O

Quantification O
and O
Statistical O
Analysis O
Statistical O
analyses O
were O
performed O
in O
R. O
Small O
sets O
of O
continuous O
variables O
, O
such O
as O
qPCR O
and O
miR-125b-5p O
validation O
experiments O
, O
were O
tested O
using O
Welch O
’ O
s O
Two O
Sample O
t O
test O
( O
because O
in O
most O
cases O
, O
equal O
variance O
could O
not O
be O
assumed O
; O
R/t.test O
) O
and O
ANOVA O
; O
statistical O
significance O
was O
assumed O
at O
p O
< O
0.05 O
. O

For O
sequencing O
count O
data O
, O
the O
negative O
binomial O
generalized O
linear O
model O
was O
tested O
using O
the O
R/DESeq2 O
package O
( O
“ O
Wald O
” O
test O
including O
log-fold O
change O
shrinkage O
) O
to O
detect O
differentially O
expressed O
miRs O
, O
using O
the O
supplied O
independent O
filtering O
and O
correction O
for O
multiple O
testing O
at O
an O
alpha O
level O
of O
0.1 O
. O

In O
cases O
where O
additional O
power O
was O
desirable O
or O
p O
values O
could O
not O
be O
obtained O
by O
other O
means O
( O
transcriptome O
meta-analysis O
, O
whole O
genome O
miR-targeting O
) O
, O
permutation O
analysis O
was O
performed O
. O

This O
comprised O
random O
assignment O
of O
test O
variables O
in O
the O
same O
size O
as O
the O
original O
test O
set O
and O
repeating O
the O
analysis O
for O
a O
large O
number O
of O
times O
, O
such O
that O
a O
null O
distribution O
of O
values O
could O
be O
generated O
, O
which O
can O
be O
used O
to O
determine O
a O
false O
discovery O
ratio O
for O
the O
original O
result O
. O

Statistical O
significance O
was O
assumed O
at O
p O
< O
0.05. O
qPCR O
of O
ChAT/vAChT O
mRNA O
against O
housekeeping O
in O
LA-N-2 O
, O
p O
values O
are O
found O
in O
Results O
( O
Welch O
two-sample O
t O
test O
) O
: O
Chat O
, O
Day O
2 O
, O
10 O
ng/ml O
, O
t O
= O
−3.2436 O
, O
df O
= O
4.9872 O
; O
100 O
ng/ml O
, O
t O
= O
−2.349 O
, O
df O
= O
4.1296 O
; O
Day O
3 O
, O
10 O
ng/ml O
, O
t O
= O
−2.8481 O
, O
df O
= O
6.9658 O
; O
100 O
ng/ml O
, O
t O
= O
−6.3786 O
, O
df O
= O
3.3998 O
; O
Day O
4 O
, O
100 O
ng/ml O
, O
t O
= O
−9.0836 O
, O
df O
= O
6.9835. O
vAChT O
, O
Day O
2 O
, O
t O
= O
5.9222 O
, O
df O
= O
5.3619 O
; O
Day O
4 O
, O
t O
= O
7.1016 O
, O
df O
= O
4.8784 O
. O

Number O
of O
biological O
replicates O
: O
4. O
qPCR O
of O
ChAT O
mRNA O
against O
housekeeping O
in O
LA-N-5 O
, O
p O
values O
are O
found O
in O
Figure O
S2 O
legend O
( O
Welch O
two-sample O
t O
test O
) O
: O
Day O
2 O
, O
10 O
ng/ml O
, O
t O
= O
−4.5204 O
, O
df O
= O
3.059 O
; O
Day O
4 O
, O
10 O
ng/ml O
, O
t O
= O
−4.7639 O
, O
df O
= O
5.0369 O
; O
100 O
ng/ml O
, O
t O
= O
−4.9161 O
, O
df O
= O
2.0262 O
. O

Number O
of O
biological O
replicates O
: O
4 O
. O

Mean O
absolute O
count-change O
LA-N-5 O
versus O
LA-N-2 O
, O
text O
of O
Figure O
3 O
( O
Welch O
two-sample O
t O
test O
) O
: O
t O
= O
2.6183 O
, O
df O
= O
1108 O
. O

Number O
of O
compared O
miRs O
: O
490 O
. O

Target O
count O
of O
families O
, O
Figure O
5A O
: O
enriched O
in O
both O
versus O
enriched O
in O
one O
cell O
, O
t O
= O
3.1831 O
, O
df O
= O
73 O
; O
enriched O
in O
mir-10 O
versus O
enriched O
in O
other O
sex-independent O
families O
, O
t O
= O
−3.28 O
, O
df O
= O
7.1879 O
. O

Number O
of O
compared O
families O
: O
17 O
( O
5 O
versus O
12 O
) O
. O

Validation O
of O
miR-125b-5p O
targeting O
of O
AChE O
, O
p O
values O
are O
found O
in O
Results O
( O
one-way O
ANOVA O
) O
: O
Figure O
6B O
, O
n O
= O
4 O
, O
f-ratio O
value O
9.19882 O
, O
df O
between O
treatments O
2 O
, O
within O
treatments O
9 O
; O
Figure O
6C O
, O
control O
n O
= O
5 O
, O
125b O
n O
= O
4 O
, O
132 O
n O
= O
3 O
, O
f-ratio O
value O
11.59814 O
, O
df O
between O
treatments O
2 O
, O
within O
treatments O
8 O
. O

N O
refers O
to O
biological O
replicates O
. O

Data O
and O
Code O
Availability O
The O
code O
and O
additional O
supplementary O
materials O
generated O
during O
this O
study O
are O
available O
at O
https O
: O
//github.com/slobentanzer/integrative-transcriptomics O
. O

The O
sequencing O
datasets O
generated O
during O
this O
study O
are O
available O
at O
NCBI O
GEO O
: O
GSE120520 O
and O
GSE132951 O
. O

Accompanying O
website O
: O
https O
: O
//slobentanzer.github.io/cholinergic-neurokine O

